{"id":"https://openalex.org/W2087947321","doi":"https://doi.org/10.1158/1535-7163.mct-14-0715","title":"A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies","display_name":"A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies","alternate_titles":[],"publication_year":2015,"publication_date":"2015-03-01","ids":{"openalex":"https://openalex.org/W2087947321","doi":"https://doi.org/10.1158/1535-7163.mct-14-0715","mag":"2087947321","pmid":"https://pubmed.ncbi.nlm.nih.gov/25552368"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-14-0715","doi":"https://doi.org/10.1158/1535-7163.mct-14-0715","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0715","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2087947321"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008880709","display_name":"Xuejun Fan","orcid":"https://orcid.org/0009-0001-4648-0287","observed_orcids":["https://orcid.org/0009-0001-4648-0287"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xuejun Fan","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006980380","display_name":"Randall J. Brezski","orcid":"https://orcid.org/0000-0003-4028-4741","observed_orcids":["https://orcid.org/0000-0003-4028-4741"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Randall J. Brezski","raw_affiliation_strings":["2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100707556","display_name":"Hui Deng","orcid":"https://orcid.org/0000-0003-2178-939X","observed_orcids":["https://orcid.org/0000-0003-2178-939X"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hui Deng","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003997918","display_name":"Pooja M. Dhupkar","orcid":"https://orcid.org/0000-0002-9290-7069","observed_orcids":["https://orcid.org/0000-0002-9290-7069"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pooja M. Dhupkar","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080559983","display_name":"Yun Shi","orcid":"https://orcid.org/0000-0003-1925-4337","observed_orcids":["https://orcid.org/0000-0003-1925-4337"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yun Shi","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044427647","display_name":"Anneliese O Gonzalez","orcid":"https://orcid.org/0000-0003-0143-1542","observed_orcids":["https://orcid.org/0000-0003-0143-1542"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anneliese Gonzalez","raw_affiliation_strings":["3Division of Oncology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Oncology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100690356","display_name":"Songlin Zhang","orcid":"https://orcid.org/0000-0002-5301-8090","observed_orcids":["https://orcid.org/0000-0002-5301-8090"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Songlin Zhang","raw_affiliation_strings":["4Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, Texas","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041313796","display_name":"Michael A. Rycyzyn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Rycyzyn","raw_affiliation_strings":["2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044774669","display_name":"William R. Strohl","orcid":"https://orcid.org/0000-0002-8271-6875","observed_orcids":["https://orcid.org/0000-0002-8271-6875"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William R. Strohl","raw_affiliation_strings":["2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013675555","display_name":"Robert E. Jordan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert E. Jordan","raw_affiliation_strings":["2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biologics Research, Janssen R&D, LLC, Spring House, Pennsylvania","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100320378","display_name":"Ningyan Zhang","orcid":"https://orcid.org/0000-0002-4348-2180","observed_orcids":["https://orcid.org/0000-0002-4348-2180"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ningyan Zhang","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026356376","display_name":"Zhiqiang An","orcid":"https://orcid.org/0000-0001-9309-2335","observed_orcids":["https://orcid.org/0000-0001-9309-2335"]},"institutions":[{"id":"https://openalex.org/I4405281163","display_name":"Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases","ror":"https://ror.org/03z258t47","country_code":"US","type":"facility","lineage":["https://openalex.org/I4405281163","https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Zhiqiang An","raw_affiliation_strings":["1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, Houston, Texas","institution_ids":["https://openalex.org/I4405281163"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.3441,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.77688516,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"14","issue":"3","first_page":"681","last_page":"691"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8420000076293945},{"id":"https://openalex.org/keywords/ide","display_name":"ide","score":0.6990000009536743},{"id":"https://openalex.org/keywords/matrix-metalloproteinases","display_name":"matrix metalloproteinases","score":0.8259999752044678},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8479999899864197},{"id":"https://openalex.org/keywords/fc-region","display_name":"Fc fragment","score":0.5879999995231628},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.6679999828338623},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.9200000166893005},{"id":"https://openalex.org/keywords/fc-engineered-antibody","display_name":"Fc-engineered antibody","score":0.6589999794960022},{"id":"https://openalex.org/keywords/antibody-resistance","display_name":"antibody resistance","score":0.39899998903274536},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7839999794960022},{"id":"https://openalex.org/keywords/xenograft-tumor-model","display_name":"xenograft tumor model","score":0.7519999742507935}],"concepts":[{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6420246362686157},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.60648113489151},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.6059518456459045},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5843849182128906},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.5635358095169067},{"id":"https://openalex.org/C2777092746","wikidata":"https://www.wikidata.org/wiki/Q5939625","display_name":"Humanized antibody","level":4,"score":0.5342333316802979},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.51510089635849},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5113779902458191},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5051856637001038},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.47378966212272644},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.47075799107551575},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.4628232419490814},{"id":"https://openalex.org/C125823703","wikidata":"https://www.wikidata.org/wiki/Q1616930","display_name":"Fragment crystallizable region","level":3,"score":0.4148571789264679},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39132100343704224},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3309805691242218},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0636771023273468},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020782","descriptor_name":"Matrix Metalloproteinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059748","descriptor_name":"Proteolysis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D061986","descriptor_name":"MCF-7 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-14-0715","doi":"https://doi.org/10.1158/1535-7163.mct-14-0715","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0715","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:25552368","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25552368","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.964.6815","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.964.6815","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/molcanther/14/3/681.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337415","display_name":"Janssen Research and Development","ror":"https://ror.org/03qd7mz70"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1577008882","https://openalex.org/W1620881780","https://openalex.org/W1621906926","https://openalex.org/W1977000581","https://openalex.org/W1978941237","https://openalex.org/W1980554079","https://openalex.org/W1980802782","https://openalex.org/W1993216667","https://openalex.org/W1996159926","https://openalex.org/W1996539011","https://openalex.org/W2000272838","https://openalex.org/W2003500892","https://openalex.org/W2004884683","https://openalex.org/W2005334224","https://openalex.org/W2019590981","https://openalex.org/W2027542837","https://openalex.org/W2027684043","https://openalex.org/W2035721831","https://openalex.org/W2036450767","https://openalex.org/W2039609199","https://openalex.org/W2042174846","https://openalex.org/W2054915531","https://openalex.org/W2059101015","https://openalex.org/W2059411043","https://openalex.org/W2068498906","https://openalex.org/W2076307095","https://openalex.org/W2081424327","https://openalex.org/W2081820657","https://openalex.org/W2083297935","https://openalex.org/W2114286868","https://openalex.org/W2119557232","https://openalex.org/W2128402413","https://openalex.org/W2146944629","https://openalex.org/W2149910352","https://openalex.org/W2162947594","https://openalex.org/W2167993803","https://openalex.org/W2520591007"],"related_works":["https://openalex.org/W1978941237","https://openalex.org/W2807619688","https://openalex.org/W2316208078","https://openalex.org/W1996539011","https://openalex.org/W2808696377","https://openalex.org/W4415900145","https://openalex.org/W2081362512","https://openalex.org/W2617671721"],"abstract_inverted_index":{"Primary":[0],"and":[1,29,73,146,237],"acquired":[2],"resistance":[3],"to":[4,25,52,82,91,108,215,221,238],"anticancer":[5],"antibody":[6,226,243],"immunotherapies":[7],"presents":[8,32],"significant":[9],"clinical":[10],"challenges.":[11],"Here,":[12],"we":[13,102],"demonstrate":[14],"that":[15,101],"proteolytic":[16,223],"inactivation":[17],"of":[18,55,66,125,139,150,164,198,225,242],"cancer-targeting":[19],"antibodies":[20],"is":[21],"an":[22,105,160,194,230],"unappreciated":[23],"contributor":[24],"cancer":[26,48,68,177,218,240],"immune":[27,151],"evasion,":[28],"the":[30,44,56,64,78,84,111,119,134,148,155,190,206,234],"finding":[31],"novel":[33,217],"opportunities":[34],"for":[35],"therapeutic":[36,219],"intervention.":[37],"A":[38],"single":[39],"peptide":[40],"bond":[41],"cleavage":[42],"in":[43,71,114,141,170,189,205],"IgG1":[45],"hinge":[46,99,235],"impairs":[47],"cell":[49,69],"killing":[50],"due":[51],"structural":[53],"derangement":[54],"Fc":[57],"region.":[58],"Hinge-cleaved":[59],"trastuzumab":[60,128,167,182,199],"gradually":[61],"accumulated":[62],"on":[63],"surfaces":[65],"HER2-expressing":[67],"lines":[70],"vitro,":[72],"was":[74],"greatly":[75,201],"accelerated":[76],"when":[77],"cells":[79,153,178],"were":[80],"engineered":[81],"express":[83],"potent":[85],"bacterial":[86],"IgG-degrading":[87],"proteinase":[88],"(IdeS).":[89],"Similar":[90],"cancer-related":[92],"matrix":[93],"metalloproteinases":[94],"(MMP),":[95],"IdeS":[96],"exposes":[97],"a":[98,142,171,216],"neoepitope":[100,236],"have":[103],"developed":[104],"antibody,":[106],"mAb2095-2,":[107],"specifically":[109],"target":[110],"epitope.":[112],"In":[113,130],"vitro":[115],"studies,":[116],"mAb2095-2":[117,132,165],"restored":[118,147],"lost":[120],"antibody-dependent":[121],"cell-mediated":[122],"cytotoxicity":[123],"functionality":[124],"cell-bound":[126],"single-cleaved":[127],"(scIgG-T).":[129],"vivo,":[131],"rescued":[133,166],"impaired":[135],"Fc-dependent":[136],"tumor-suppressive":[137],"activity":[138,188],"scIgG-T":[140],"xenograft":[143,207],"tumor":[144,156,173,208],"model":[145,174],"recruitment":[149],"effector":[152,227],"into":[154],"microenvironment.":[157],"More":[158],"importantly,":[159],"Fc-engineered":[161,195,231],"proteinase-resistant":[162,196],"version":[163,197],"antitumor":[168,187,203],"efficacy":[169,204],"mouse":[172],"with":[175],"human":[176],"secreting":[179],"IdeS,":[180],"whereas":[181],"alone":[183],"showed":[184],"significantly":[185],"reduced":[186],"same":[191],"model.":[192,209],"Consistently,":[193],"also":[200],"improved":[202],"Taken":[210],"together,":[211],"these":[212],"findings":[213],"point":[214],"strategy":[220],"rescue":[222],"damage":[224],"function":[228],"by":[229],"mAb":[232],"against":[233],"overcome":[239],"evasion":[241],"immunity.":[244]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2087947321","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
